Among the genitourinary cancers, renal cell carcinoma (RCC) is the seventh most common cancer in men and has a high mortality rate. The prognosis of metastatic RCC is poor, with a median survival of about 13 months and 5-year survival under 10%. However, with newer therapies, overall survival has improved. This activity reviews the evaluation and treatment of clear cell renal cell carcinoma and highlights the role of the interprofessional team in the care of patients with this condition.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/28344
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABA - 1.0 Point; Credit Type(s): Lifelong Learning (ABA)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Complex General Surgical Oncology, Cytopathology, General Pediatrics, General Surgery, Hospice & Palliative Medicine, Hospice and Palliative Medicine, Internal Medicine, Medical Oncology, Molecular Genetic Pathology, Nephrology, Pediatric Hematology-Oncology, Pediatric Nephrology, Renal/Medical Renal
Subscribe
Login
0 Comments
Oldest